Cogent Biosciences, Inc.
US ˙ NasdaqGS ˙ US19240Q2012

SecurityCOGT / Cogent Biosciences, Inc.
InstitutionQube Research & Technologies Ltd
Latest Disclosed Ownership394,000 shares
Latest Disclosed Value $ 15,165,060
Qube Research & Technologies Ltd reports 42.38% increase in ownership of COGT / Cogent Biosciences, Inc.

On May 15, 2026 - Qube Research & Technologies Ltd filed a 13F-HR form disclosing ownership of 394,000 shares of Cogent Biosciences, Inc. (US:COGT) valued at $15,165,060 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 276,728 shares of Cogent Biosciences, Inc.. This represents a change in shares of 42.38% during the quarter. The current value of the position is $12,710,440 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F COGENT BIOSCIENCES COM 19240Q201 394,000 117,272 42.38 15,165 54.29 0.0169
2026-02-17 2025-12-31 13F COGENT BIOSCIENCES COM 19240Q201 276,728 163,070 143.47 9,829 502.27 0.0100
2025-11-14 2025-09-30 13F COGENT BIOSCIENCES COM 19240Q201 113,658 94,756 501.30 1,632 1,108.89 0.0017
2025-08-14 2025-06-30 13F COGENT BIOSCIENCES COM 19240Q201 18,902 18,902 136 0.0001
2024-08-14 2024-06-30 13F COGENT BIOSCIENCES COM 19240Q201 0 -123,017 -100.00 0 -100.00
2024-05-14 2024-03-31 13F COGENT BIOSCIENCES COM 19240Q201 123,017 5,849 4.99 827 20.06 0.0013
2024-02-13 2023-12-31 13F COGENT BIOSCIENCES COM 19240Q201 117,168 117,168 689 0.0013
2022-02-10 2021-12-31 13F/A-1 COGENT BIOSCIENCES COM 19240Q201 0 -38,213 -100.00 0 -100.00
2022-02-01 2021-12-31 13F COGENT BIOSCIENCES COM 19240Q201 0 -38,213 0
2021-11-12 2021-09-30 13F COGENT BIOSCIENCES COM 19240Q201 38,213 -17,374 -31.26 321 -28.82 0.0040
2021-08-13 2021-06-30 13F COGENT BIOSCIENCES COM 19240Q201 55,587 6,546 13.35 451 4.64 0.0051
2021-05-14 2021-03-31 13F UNUM THERAPEUTICS COM 19240Q201 49,041 49,041 431 0.0068
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.